Rationale for Using Immunotherapy in the Treatment of ES-SCLC

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Professor Keith M. Kerr on fine points of testing for EGFR exon 20 insertion mutations in management of advanced NSCLC, commentary from Clinical Care Options (CCO)

Keith M. Kerr, MB ChB, FRCPath, FRCPE Released: August 5, 2021

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

On-demand webcast from a live CCO webinar capturing global perspectives from Drs. Edward S. Kim and Luis Paz-Ares on the optimal management of patients with EGFR+ NSCLC

Edward S. Kim, MD, FACP, FASCO Luis Paz-Ares, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: July 29, 2021 Expired: July 28, 2022